Abstract: The present invention provides a pluripotent stem cell or a derivative thereof. A first nucleic acid molecule is introduced into a genome of the pluripotent stem cell or the derivative thereof; and a second nucleic acid molecule is introduced to a 3?UTR region of an immune response-related gene in the pluripotent stem cell or the derivative thereof. The first nucleic acid molecule encodes a small nucleic acid molecule that mediates RNA interference, and the small nucleic acid molecule can specifically bind to a transcript product of the second nucleic acid molecule to start an RNA interference program to degrade or silence mRNA of the immune response-related gene, thereby blocking the expression of the immune response-related gene, such that the cell has immunological compatibility, and thus can eliminate or reduce alloimmune rejection responses.

Abstract: Provided is an immunologically compatible and reversible universal pluripotent stem cell or a derivative thereof. An inducible gene expression system and the expression sequence of at least one immunologically compatible molecule are introduced into the genome of the pluripotent stem cell or the derivative thereof. The immunologically compatible molecule is used to regulate the expression of immune response-related genes in the pluripotent stem cell or the derivative thereof. The expression of the immunologically compatible molecule is regulated by the inducible gene expression system. The described method can increase the immunological compatibility between a transplant and a recipient, and can simultaneously reversibly restore the antigen-presenting abilities of transplant cells.

Abstract: The present invention relates to a non-viral iPSCs induction method as well as the compositions, kits and iPSCs obtained therefrom. More specifically, the induction method comprises the following steps: 1) Constructing a recombinant plasmid by introducing the DNA sequences expressing the reprogramming factors POU5F1, SOX2, GLIS1, KLF4, MYCL and hsa-miR-302s into an episomal vector; 2) Obtaining iPSCs by introducing the recombinant plasmids obtained in step 1) into human somatic cells, and reprogramming induction culture of the cells. The method reduces the risk of clinical applications of iPSCs by using a combination of highly-safe reprogramming factors without the introduction of high-risk reprogramming factors such as c-MYC, SV40-LT and TP53 inhibitors; The method is highly applicable.

Abstract: The present invention relates to a non-viral iPSCs induction method as well as the compositions, kits and iPSCs obtained therefrom. More specifically, the induction method comprises the following steps: 1) Constructing a recombinant plasmid by introducing the DNA sequences expressing the reprogramming factors POU5F1, SOX2, GLIS1, KLF4, MYCL and hsa-miR-302s into an episomal vector; 2) Obtaining iPSCs by introducing the recombinant plasmids obtained in step 1) into human somatic cells, and reprogramming induction culture of the cells. The method reduces the risk of clinical applications of iPSCs by using a combination of highly-safe reprogramming factors without the introduction of high-risk reprogramming factors such as c-MYC, SV40-LT and TP53 inhibitors; The method is highly applicable.

Abstract: The present invention relates to a non-viral iPSCs induction method as well as the compositions, kits and iPSCs obtained therefrom. More specifically, the induction method comprises the following steps: 1) Constructing a recombinant plasmid by introducing the DNA sequences expressing the reprogramming factors POU5F1, SOX2, GLIS1, KLF4, MYCL and hsa-miR-302s into an episomal vector; 2) Obtaining iPSCs by introducing the recombinant plasmids obtained in step 1) into human somatic cells, and reprogramming induction culture of the cells. The method reduces the risk of clinical applications of iPSCs by using a combination of highly-safe reprogramming factors without the introduction of high-risk reprogramming factors such as c-MYC, SV40-LT and TP53 inhibitors; The method is highly applicable.

Abstract: A transducer array is connected with a catheter housing. As the transducer array is rotated, the catheter housing also rotates. As a result, at least a portion of the catheter housing twists about a longitudinal axis. By applying rotation in a controlled way, such as with a motor, a plurality of two-dimensional images for three-dimensional reconstruction may be obtained. The rotation of the catheter housing may limit the total amount of rotation of the array, such as rotating the array through a 90 degree or less amount of rotation about the longitudinal axis. The housing of the catheter is formed with a soft section. The softer material allows for a greater amount or increased ease for twisting the catheter.

Abstract: A transducer array is connected with a catheter housing. As the transducer array is rotated, the catheter housing also rotates. As a result, at least a portion of the catheter housing twists about a longitudinal axis. By applying rotation in a controlled way, such as with a motor, a plurality of two-dimensional images for three-dimensional reconstruction may be obtained. The rotation of the catheter housing may limit the total amount of rotation of the array, such as rotating the array through a 90 degree or less amount of rotation about the longitudinal axis. The housing of the catheter is formed with a soft section. The softer material allows for a greater amount or increased ease for twisting the catheter.